|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prat J: Ovarian carcinomas: Five distinct
diseases with different origins, genetic alterations, and
clinicopathological features. Virchows Arch. 460:237–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katz B, Tropé CG, Reich R and Davidson B:
MicroRNAs in ovarian cancer. Hum Pathol. 46:1245–1256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen D, Danquah M, Chaudhary AK and Mahato
RI: Small molecules targeting microRNA for cancer therapy: Promises
and obstacles. J Control Release. 219:237–247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohtsuka M, Ling H, Doki Y, Mori M and
Calin GA: MicroRNA processing and human cancer. J Clin Med.
4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li MH, Fu SB and Xiao HS: Genome-wide
analysis of microRNA and mRNA expression signatures in cancer. Acta
Pharmacol Sin. 36:1200–1211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar
|
|
10
|
Orellana EA and Kasinski AL: MicroRNAs in
Cancer: A historical perspective on the path from discovery to
therapy. Cancers (Basel). 7:1388–1405. 2015. View Article : Google Scholar
|
|
11
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kishikawa T, Otsuka M, Ohno M, Yoshikawa
T, Takata A and Koike K: Circulating RNAs as new biomarkers for
detecting pancreatic cancer. World J Gastroenterol. 21:8527–8540.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hollis M, Nair K, Vyas A, Chaturvedi LS,
Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer:
Early detection, prognosis, and chemosensitivity. World J
Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Braza-Boïls A, Marí-Alexandre J, Gilabert
J, Sánchez-Izquierdo D, España F, Estellés A and Gilabert-Estellés
J: MicroRNA expression profile in endometriosis: Its relation to
angiogenesis and fibrinolytic factors. Hum Reprod. 29:978–988.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suryawanshi S, Vlad AM, Lin HM,
Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel
M, Lee T, et al: Plasma microRNAs as novel biomarkers for
endometriosis and endometriosis-associated ovarian cancer. Clin
Cancer Res. 19:1213–1224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vaksman O, Stavnes HT, Kaern J, Trope CG,
Davidson B and Reich R: miRNA profiling along tumour progression in
ovarian carcinoma. J Cell Mol Med. 15:1593–1602. 2011. View Article : Google Scholar
|
|
19
|
Zou J, Yin F, Wang Q, Zhang W and Li L:
Analysis of microarray-identified genes and microRNAs associated
with drug resistance in ovarian cancer. Int J Clin Exp Pathol.
8:6847–6858. 2015.PubMed/NCBI
|
|
20
|
Ye M and Zhang J and Zhang J, Miao Q, Yao
L and Zhang J: Curcumin promotes apoptosis by activating the
p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer.
Cancer Lett. 357:196–205. 2015. View Article : Google Scholar
|
|
21
|
Zhu T, Yuan J, Wang Y, Gong C, Xie Y and
Li H: MiR-661 contributed to cell proliferation of human ovarian
cancer cells by repressing INPP5J expression. Biomed Pharmacother.
75:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang X, Liu P, Zhang B, Mao H, Shen L and
Ma Y: Inhibitory effects of STAT3 decoy oligodeoxynucleotides on
human epithelial ovarian cancer cell growth in vivo. Int J Mol Med.
32:623–628. 2013.PubMed/NCBI
|
|
23
|
Chen Z, Liu X, Hu Z, Wang Y, Liu M, Liu X,
Li H, Ji R, Guo Q and Zhou Y: Identification and characterization
of tumor suppressor and oncogenic miRNAs in gastric cancer. Oncol
Lett. 10:329–336. 2015.PubMed/NCBI
|
|
24
|
Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y,
Wang YX, Qi P and Xu S: Aberrant miR-215 expression is associated
with clinical outcome in breast cancer patients. Med Oncol.
31:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang H, Li Y, Luo RY and Shen FJ:
MicroRNA-215 is a potential prognostic marker for cervical cancer.
J Huazhong Univ Sci Technolog Med Sci. 34:207–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu YJ and Fan Y: MiR-215/192 participates
in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015.
View Article : Google Scholar
|
|
27
|
Wang JH, Nao JF, Zhang M and He P:
20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer
HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol.
35:11985–11994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miyamoto M, Takano M, Iwaya K, Shinomiya
N, Kato M, Aoyama T, Sasaki N, Goto T, Suzuki A, Hitrata J, et al:
X-chromosome-linked inhibitor of apoptosis as a key factor for
chemoresistance in clear cell carcinoma of the ovary. Br J Cancer.
110:2881–2886. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pang Y, Si M, Sun B, Niu L, Xu X, Lu T,
Yuan H and Lou H: DHA2, a synthesized derivative of bisbibenzyl,
exerts antitumor activity against ovarian cancer through inhibition
of XIAP and Akt/mTOR pathway. Food Chem Toxicol. 69:163–174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ayyagari VN and Brard L: Bithionol
inhibits ovarian cancer cell growth in vitro - studies on
mechanism(s) of action. BMC Cancer. 14:612014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Farrand L, Kim JY, Byun S, Im-Aram A, Lee
J, Suh JY, Lee KW, Lee HJ and Tsang BK: The diarylheptanoid
hirsutenone sensitizes chemoresistant ovarian cancer cells to
cisplatin via modulation of apoptosis-inducing factor and X-linked
inhibitor of apoptosis. J Biol Chem. 289:1723–1731. 2014.
View Article : Google Scholar :
|
|
32
|
Pang Y, Mao H, Shen L, Zhao Z, Liu R and
Liu P: MiR-519d represses ovarian cancer cell proliferation and
enhances cisplatin-mediated cytotoxicity in vitro by targeting
XIAP. Onco Targets Ther. 7:587–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
